Results 41 to 50 of about 7,965 (181)

Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine

Histopathology, EarlyView.
CYP11B2 immunohistochemistry identifies aldosterone‐producing nodules and enables objective subtyping using the B2 ratio (B2R), defined as the size ratio between the largest and second‐largest CYP11B2‐positive nodules. A B2R ≥8.1 indicates classical histology with a dominant lesion and high likelihood of cure, whereas B2R <8.1 reflects non‐classical ...
Adam Stenman, Tim Nilsson, Henrik Falhammar, C. Christofer Juhlin   +3 more
wiley   +1 more source

Advances in the biochemical diagnostics of primary aldosteronism: from immunoassays to steroidomics and proteomics

Frontiers in Endocrinology
Primary aldosteronism is the most common cause of secondary hypertension, yet most cases remain unrecognized and left without optimal treatment. The diagnostic inertia may be attributed to the lack of specific symptoms, insufficient awareness among ...
Alicja Szatko, Alicja Szatko, Alicja Szatko, Agata Toboła, Henrik Falhammar, Henrik Falhammar, Wojciech Zgliczyński, Piotr Glinicki, Piotr Glinicki   +8 more
doaj   +1 more source

Primary aldosteronism and obstructive sleep apnea: What do we know thus far?

Frontiers in Endocrinology, 2022
Both primary aldosteronism and obstructive sleep apnea are well-known causes of hypertension and contribute to increased cardiovascular morbidity and mortality independently.
Huai Heng Loh, Huai Heng Loh, Norlela Sukor   +2 more
doaj   +1 more source

Improving primary aldosteronism diagnosis and treatment: outcomes from an endocrine hypertension service

Internal Medicine Journal, EarlyView.
Abstract Aims To evaluate the sustained impact of the Endocrine Hypertension Service on primary aldosteronism (PA) diagnosis and management over a subsequent 3‐year period. Background PA is a prevalent yet underdiagnosed cause of secondary hypertension, associated with increased cardiovascular, renal and metabolic risk. Limited awareness, resources and
Minn W. Chow, Chrislyn Ng, Jimmy Shen, Peter J. Fuller, Jun Yang, Renata Libianto   +5 more
wiley   +1 more source

A scoping review of specialist hypertension clinics

Internal Medicine Journal, EarlyView.
Abstract Background Hypertension is an important preventable risk factor for cardiovascular and kidney disease, with limited data regarding the impact on blood pressure (BP) control following management in specialist hypertension clinics globally. Aims To summarise current literature on BP outcomes in SHCs and identify gaps in evidence.
Destiny O'Dea, Andrew Siyoung Chung, Arunima Jain, Amy Kang, Zoltan Endre, Sradha Kotwal   +5 more
wiley   +1 more source

Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real‐world observational study

Journal of Diabetes Investigation, EarlyView.
This real‐world observational study enrolled 256 patients with type 2 diabetes and chronic kidney disease (T2D‐CKD). After 12 months of finerenone treatment, 45 patients completed follow‐up. Finerenone was associated with significant improvements in insulin resistance markers (HOMA‐IR, TyG index), lipid profile (LDL‐C), glycemic control (HbA1c), and ...
Xin Zhao, Bohan Liu, Ran Sun, Yaxuan Shi, Ya Liu   +4 more
wiley   +1 more source

Primary aldosteronism with hypokalemic rhabdomyolysis: a case report and review of the literature

Journal of Medical Case Reports
Background Hypokalemic rhabdomyolysis is a rare clinical manifestation of primary aldosteronism, making its diagnosis challenging, particularly when it becomes the primary presenting symptom.
Pingan Shi, Chao Wang, Yuanjun Lyu
doaj   +1 more source

Unmasking Hormonal Mechanisms of Hypertension in Obesity

JACC: Basic to Translational Science
Summary: Understanding hormonal mechanisms of obesity-related hypertension may inform targeted therapy. Participants with obesity and hypertension underwent deep-phenotyping procedures to detect the primary aldosteronism phenotype, low-renin phenotype ...
Stéfanie Parisien-La Salle, MD, Cheng-Hsuan Tsai, MD, Andrew J. Newman, MD, Justin M. Chan, MD, Julia Milks, MD, Gail Adler, MD, PhD, Arnaldo Ferrebus, BA, Isabelle Hanna, BA, Sanan Mahrokhian, BA, Bertram Pitt, MD, Jenifer M. Brown, MD, Anand Vaidya, MD   +11 more
doaj   +1 more source

Case report: Percutaneous adrenal arterial embolization cures resistant hypertension

Frontiers in Cardiovascular Medicine, 2022
BackgroundPrimary aldosteronism is a common cause of resistant hypertension. Patients with primary aldosteronism due to aldosterone-producing adenoma are generally treated with unilateral adrenalectomy or medical therapy.
Yaqiong Zhou, Yaqiong Zhou, Dan Wang, Dan Wang, Qiting Liu, Qiting Liu, Jixin Hou, Jixin Hou, Peijian Wang, Peijian Wang   +9 more
doaj   +1 more source

Aldosterone and Cardiovascular Risk Across the Lifespan

Metabolites
Aldosterone excess, particularly in the context of primary aldosteronism, is associated with adverse cardiovascular outcomes. Historically considered a condition of resistant hypertension with hypokalaemia, patients with primary aldosteronism often ...
Roshan A. Ananda, Trevor A. Mori, Jun Yang   +2 more
doaj   +1 more source